Medtech industry veteran, John Lipman is the new Chief Executive Officer. Bodyport co-founder, Corey Centen, will continue as President and also serve as Chief Technology Officer (CTO) of the company.
John Lipman’s appointment comes as Bodyport prepares for commercialization of its proprietary Bodyport Cardiac Scale™, an innovative technology that remotely and noninvasively assesses heart function and fluid status in people living with fluid management conditions.
“I joined Bodyport to help make a difference in patients’ lives. I truly believe our simple, intuitive biomarker platform will be able to do just that,” Lipman said. “Bodyport’s growing clinical evidence and commitment to a robust clinical roadmap have the potential to help detect heart failure events accurately and catch them earlier from the comfort of the patient’s home. I look forward to working together with our incredibly talented team and am eager to bring our solutions to market.”
John Lipman joins Bodyport with more than 25 years of leadership experience, including developing and leading pre-launch and commercial companies across the medical device industry.
“I am delighted to welcome John to the team during this important phase of our growth,” Centen said. “In my new role as President and CTO, I am excited to lead the development of our novel biomarker pipeline and prediction algorithms for managing cardiorenal conditions.”
Most recently, Lipman was the President of North America for Quanta Dialysis Technologies where he led the company’s commercial operations and activities in the U.S. Prior to his time at Quanta, Lipman was Chief Commercial Officer at NightBalance for four years before its acquisition by Philips, where he was responsible for leading the U.S. launch of the Lunoa sleep therapy device. He was also Vice President of marketing and sales at ApniCure, where he deployed and expanded a U.S. sales team to launch a new treatment for obstructive sleep apnea. Lipman has also held positions at FoxHollow Technologies and two Johnson & Johnson subsidiaries, LifeScan and Scios. He graduated from California Polytechnical State University and holds an MBA in Marketing from the University of San Francisco.
“John’s extensive industry experience will prove to be a valuable resource to the Bodyport team,” said Phyllis Whiteley, Ph.D., Chair of Bodyport’s board of directors. “We are excited to welcome John as Bodyport’s CEO and look forward to him accelerating the commercialization of Bodyport’s solutions to improve heart failure management.”
Bodyport is a biomarker-guided digital therapeutics company on a mission to address complex chronic conditions by embedding a sophisticated biomarker platform into simple, easy-to-use devices. Bodyport captures hemodynamic signals through the Cardiac Scale to power optimized interventions tailored to the patient. By not requiring a wearable device or surgical implant, the solution seamlessly integrates into a patient’s daily life.
Bodyport is focused on keeping patients with cardiorenal conditions healthier and out of the hospital. The company is tackling heart failure first to noninvasively assess heart function and fluid status in a single step at home. Bodyport is HIPAA compliant and has received SOC2 Type 2 certification.
Based in San Francisco, the company is backed by top-tier investors such as Boehringer Ingelheim Venture Fund, Playground Global, Initialized Capital, Y Combinator, and Rock Health.